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The Research Investments in Global Health (ResIn, www.researchinvestments.org) study analyses funding trends in
health research, with a predominant focus on infectious diseases. Since October 2015, the project is funded by the
Bill & Melinda Gates Foundation and is now based at the University of Southampton in the UK. In 2016, Public
Policy@Southampton provided ResIn with a small grant to explore developing links with policy, funding and
research stakeholders with an interest in global health. Three meetings were organised in London (Wellcome Trust,
25 May 2016), Brussels (UK Research Office, 2 June 2016), and Geneva (WHO R&D Observatory, 8 June 2016). In total,
45 stakeholders attended and provided comment and critique on the study methodology and potential expansion
into other disciplines. A theme that emerged across all three meetings concerned the use of a standardised
categorisation system. A key benefit of the ResIn study is the ability to present granular detail in precise areas.
Further work packages that could enhance the use of the collected R&D data included integration with geospatial,
policy and scientometric methodologies. There was broad enthusiasm that outputs from these proposed projects
would provide clear benefits in informing health policy and R&D strategy. Outputs from the ongoing study
covering infection-related R&D investments in the G20 nations will be available in 2017.Background
The Research Investments in Global Health study
(ResIn, www.researchinvestments.org) has systematically
mapped the UK landscape for infectious disease research
by describing funding trends for awards to UK institu-
tions between 1997 and 2013 inclusive [1, 2]. Awards re-
lated to infection from all the major funders of health
and biomedical research were categorised by disease
area, pathogen, clinical specialty and the type of science
along the R&D pipeline. Investments were also com-
pared to the global burden of disease, using data sourced
from the Global Burden of Disease (GBD) study [3, 4],
to gain an idea of UK areas of likely research strength
and diseases that appear relatively poorly-funded.* Correspondence: m.head@soton.ac.uk
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(http://creativecommons.org/publicdomain/zeSince October 2015, ResIn has been funded by the Bill
& Melinda Gates Foundation to consider R&D invest-
ments for infection across all the G20 nations. In 2016,
Public Policy @ Southampton (http://www.southampto-
n.ac.uk/publicpolicy) awarded ResIn a small grant
(£3900) to organise three workshops that engage fun-
ders, policymakers and other stakeholders in global
health. With a combined attendance of 45 individuals
(Tables 1, 2, and 3), the aim of the workshops was to
highlight the activity of the ResIn project, to prepare the
R&D community for the publication of the global data-
set in 2017, to present ideas for expansion into other
disciplines, and to seek critique and feedback on study
methodology.
Discussions centred around two themes – method-
ology, and wider engagement with the research, fund-
ing and policy communities. The material presented
at the workshops is provided here (supplementary
information).le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Invited attendees of London workshop, 25 May 2016
Alex Blum Public Policy @ Southampton
Gavin Costigan Public Policy @ Southampton
Catherine Cotton Federation of European Microbiological
Societies
Kevin Dolby Wellcome Trust
Emily Gale Medical Research Council
Pat Goodwin Microbiology Society
Felix Greaves Public Health England
Chris Lowry British Society of Immunology
Anthony Scott London School of Hygiene & Tropical Medicine
Andrew Smith Foreign and Commonwealth Office
Vinny Smith Meningitis Research Foundation
Neil Squires Faculty of Public Health
Sophie Taysom Department of Health
Charlotte Watts UK Department for International Development
Philip Price Wellcome Trust
Graham Tynan Wellcome Trust
Marco De
Ambrogi
The Lancet Infectious Diseases
John Broughall Antibiotic Research UK
Mark Zuckerman Clinical Virology Network
Table 3 Invited attendees of Geneva workshop, 8 June 2016
Taghreed Adam WHO Global Observatory on Health R&D
Lauranne Botti COHRED
Vania de la Fuente
Nunez
WHO Global Observatory on Health R&D
Nebiat Gebreselassie WHO Global TB Programme
Abdul Ghaffar WHO Alliance for Health Policy and Systems
Research
Hope Johnson GAVI
Christian Leindhart WHO Global TB Programme
Manuel Martin UAEM
Maya Matthews European Commission
Deepak Mattur UNAIDS
Amit Prasad WHO Global Observatory on Health R&D
Alistair Robb WHO Information, Evidence and Research
Robert Terry Special Programme for Research and Training
in Tropical Diseases (TDR)
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A theme that emerged across all three meetings con-
cerned the use of a standardised categorisation system–
comment included that ResIn should adopt an existing
system (such as that used by the NIH, Health Research
Classification System or MESH terms) and work towards
a unified categorisation methodology. The ResIn project
created its own system which would cover many of the
keyword and disease areas used by the otherTable 2 Invited attendees of Brussels workshop, 2 June 2016
Jozef Anne Federation of European Microbiological
Societies
Brendan Barnes European Federation of Pharmaceutical
Industries and Associations
Roberto Bertollini WHO Brussels office
Julie Cantalou Public Policy@Southampton
Laurence Colin European Research Council
Alain Deleener Research Foundation - Flanders (FWO)
Evelyn Depoortere European Commission
Maribel Glogowoski UK Research Office
Oliver Karsten Friends of the Global Fund Europe
Barbara Kerstiens European Commission
Hugh Laverty Innovative Medicines Initiative
Kevin McCarthy European Commission
Martine Sabbe Scientific Institute of Public Healthclassifications; however, there was general agreement
that it would be useful if a standardised system could be
introduced that remained comprehensive but with flexi-
bility to adapt as research investment analyses evolve.
This could be an activity developed in collaboration with
the WHO R&D Observatory.
Further category development would be useful to draw
out further granular detail for highlighting specific sub-
sections of data, for example further breakdown of the
public health category to illustrate investments directed
towards social science, epidemiology, economics etc; one
further example was to differentiate between primary
data collection and secondary data analysis. A possible
weighting system to allocate proportional amounts of
funding across pathogens was suggested e.g. £1 m study
relating to co-infection of HIV and tuberculosis would
see £500 k towards HIV and £500 k towards tubercu-
losis. This would be more difficult to achieve across
cross-cutting themes (such as global health and anti-
microbial resistance). The distribution of funds from
lead institutions to collaborators (particularly those in
low- and middle-income countries (LMICs)) is currently
difficult to systematically track but is an important factor
to consider. Additional useful analyses would include
comparison of levels of investment with i) risk factors
for disease (alongside the existing burden of disease
comparisons), ii) implementation and aid funding; iii)
projected future health burdens; iv) differences between
datasets of disease burden e.g. that produced by the In-
stitute for Health Metrics and Evaluation and the WHO; v)
awards directed straight to LMICs, including infrastructure
and other capacity-building initiatives.
The data gap of private sector data was noted, with
limited options for systematic provision of such
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ample methods developed by Prof Jonathan Grant,
King’s College London). Partnerships between the pri-
vate sector and public or charitable organisations (such
as the International Medicines Initiative or GAVI) tend
to provide some public information about industry in-
vestment. Policy Cures have also carried out surveys
with the for-profit sector to obtain such information
anonymously.
Differing levels of overheads across different sectors
will mean that the amount of money for the visible costs
of research (staff, consumables) varies between funders.
A sensitivity analysis to assess these differences would
be helpful. Another area of difficulty highlighted was the
funding flow between lead institution receiving the
award and project partners – at any large systematic
scale, this would be very complex to describe. Accessibil-
ity of data across countries is anticipated to be broadly
satisfactory, though there may be language difficulties
with some nations (Russia and China were noted exam-
ples where open data, in English, may be limited). In-
vestments directed specifically towards infrastructure to
house research activity is not directly captured as part of
the ResIn analysis, and is often difficult to attribute to
disease areas.
Project engagement with global and national
stakeholders
The ResIn analysis can drive forward the movement to-
wards open access investment data, in an accessible for-
mat. Funders and other stakeholders could be invited to
suggest further aspects of categorisation and data visuali-
sations that would be most useful. The granularity of the
data is important, and the ability to provide detailed cross-
and sub-national analyses is extremely useful. The format
in which ResIn data was made available was discussed,
with reports and papers, policy briefs and online custom-
isable visualisations all considered useful, depending on
the audience. The online visualisations, in particular, allow
users to draw data and infer conclusions in precise areas.
The presentation included possibilities for further
work packages that could enhance the data collection,
including integration with geospatial, policy and sciento-
metric methodologies. There was broad enthusiasm that
outputs from these proposed projects would provide
clear benefits in informing health policy and R&D strat-
egy. Expert input from colleagues and organisations in
resource-poor settings could identify priority projects
and areas of focus to be addressed by the ResIn study.
There was a mixed view on whether expansion of the
ResIn project should concentrate on a broad focus of
large-scale data collection and top-level analyses, or a
more defined focus on specific topic areas (e.g. infec-
tious disease) where the project can provide significantexpertise. A networking function that proactively links
stakeholders across national borders and disease areas
was also suggested as a potential benefit.
The presentation noted that funding was very reactive
in nature, and there followed suggestions that ResIn
could help to inform proactive thinking about future
R&D priorities and work alongside existing groups that
have a ‘horizon-scanning’ remit (such as the EU network
for emergency preparedness). Broader engagement with
the WHO would be particularly important, and engage-
ment with some member nations will typically be most
effective if in conjunction with the WHO.
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